SAGA Diagnostics

company

About

Liquid biopsy testing specialists. Ultrasensitive cancer diagnosis and monitoring to 0.001% variant frequency.

  • 11 - 50

Details

Last Funding Type
Seed
Last Funding Money Raised
€1M
Industries
Biotechnology,Genetics,Medical
Founded date
Jan 1, 2016
Number Of Employee
11 - 50
Operating Status
Active

SAGA Diagnostics AB is a personalized cancer diagnostics and disease monitoring company focused on molecular genetic analyses of a powerful cancer biomarker: circulating tumor DNA (ctDNA). The company was founded in 2016 as a spin-out from a highly successful research group at Lund University, with a mission to improve precision cancer medicine, provide more accurate treatment monitoring, and improve patient survival using minimally-invasive liquid biopsy cancer testing services and kits.

The SAGA team consists of renowned scientists, highly qualified staff and an experienced management team who work together to launch SAGA’s ultrasensitive services and products as part of the ongoing revolution in cancer research, drug development, and clinical diagnostics. SAGA’s proprietary tests can help patients, oncologists, and drug developers detect actionable mutations, stratify patient groups, and monitor treatment response, residual disease, and disease recurrence at an unprecedented sensitivity.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
€1M kr40M
SAGA Diagnostics has raised a total of €1M kr40M in funding over 2 rounds. Their latest funding was raised on Jun 11, 2019 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 11, 2019 Series A kr40M 2 Detail
Mar 15, 2018 Seed €1M 2 Detail

Investors

Number of Lead Investors
Number of Investors
3
SAGA Diagnostics is funded by 3 investors. Gunnar Nilsson Cancer Foundation and Faro Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Gunnar Nilsson Cancer Foundation Series A
Faro Capital Series A
Torna Kapital Seed